BOCA RATON, Fla. and TAINAN CITY, Taiwan (PRWEB)
October 16, 2020
Florida Pharmaceutical Products, LLC (FPP) a pharmaceutical company involved in the Development, Sales, Marketing and Distribution of Generic Pharmaceuticals and Standard Chem. & Pharm. Co., Ltd (Standard) a company involved in the Development, Manufacturing, Distribution, and Licensing of pharmaceuticals are pleased to announce the signing of an agreement for the Licensing, Supply and Distribution of an approved ANDA for Riluzole Tablets developed by Standard, approved by the FDA, and scheduled to launch in November.
The product has sales of approximately $5 million according to IQVIA™. The ANDA product will be sold and distributed by FPP, in the Quinn Label, within the US. “We are pleased to be working with Standard on this project and look forward to a successful launch,” said Larry J. Lapila, President of FPP. The ANDA will be manufactured by Standard. “We are pleased to partner with FPP to launch Riluzole Tablets in the US market and support our shared commitment for reliable and affordable medicines for the benefit of patients,” said Standard.
About Florida Pharmaceutical:
Florida Pharmaceutical Products, LLC (FPP) is a Boca Raton based pharmaceutical company involved in the development of Generic Pharmaceuticals seeking to gain approval and/or license of niche generic products in a broad range of therapeutic areas for marketing and distribution in the US.
Standard Chem. & Pharm. Co., Ltd (Standard) is one of the leading pharmaceutical companies in Taiwan. Standard is founded in 1967, and has been a publicly held company since 1995. A vertically integrated pharma with manufacturing capability in API and FDF products. Standard is committed to supplying reliable and high-quality drug products. Standard has been inspected by US-FDA since 2000, and supplying pharmaceutical products in the US for years.
Share article on social media or email: